News & Updates

Individuals with prediabetes or diabetes may benefit from increased dietary intake of n-3 polyunsaturated fatty acids (PUFAs), particularly alpha-linolenic acid (ALA) and docosapentaenoic acid (DPA), which help lower the risk of all-cause and cardiovascular mortality, suggests a US study.

People living with HIV (PWH) on statin therapy who have certain metabolic risk factors, such as obesity and prediabetes, are at greater risk of developing diabetes mellitus (DM), reports a study. This association is also present in those treated with placebo.

Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.

Treatment with semaglutide can significantly lower the risk of time to first heart failure (HF) events or cardiovascular (CV) death in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), a recent study has shown.

A population-based study of 146,430 Hong Kong patients with diabetes mellitus (DM) reports that optimal vs suboptimal glycaemic control is associated with reduced risk of developing hepatocellular carcinoma (HCC) and liver-related mortality.